Recognising Lung Cancer in Primary Care

Stephen H Bradley, Martyn P T Kennedy, Richard D Neal, Stephen H Bradley, Martyn P T Kennedy, Richard D Neal

Abstract

Significant advances in the management of both early and advanced stage lung cancer have not yet led to the scale of improved outcomes which have been achieved in other cancers over the last 40 years. Diagnosis of lung cancer at the earliest stage of disease is strongly associated with improved survival. Therefore, although recent advances in oncology may herald breakthroughs in effective treatment, achieving early diagnosis will remain crucial to obtaining optimal outcomes. This is challenging, as most lung cancer symptoms are non-specific or are common respiratory symptoms which usually represent benign disease. Identification of patients at risk of lung cancer who require further investigation is an important responsibility for general practitioners (GPs). Diagnosis has historically relied upon plain chest X-ray (CXR), organised in response to symptoms. The sensitivity of this modality, however, compares unfavourably with that of computed tomography (CT). In some jurisdictions screening high-risk individuals with low dose CT (LDCT) is now recommended. However uptake remains low and the eligibility for screening programmes is restricted. Therefore, even if screening is widely adopted, most patients will continue to be diagnosed after presenting with symptoms. Achieving early diagnosis requires GPs to maintain an appropriate level of suspicion and readiness to investigate in high-risk patients or those with non-resolving symptoms. This article discusses the early detection of lung cancer from a primary care perspective. We outline risk factors and epidemiology, the role of screening and offer guidance on the recognition of symptomatic presentation and the investigation and referral of suspected lung cancer.

Keywords: CT chest; Cancer diagnosis; Chest X-ray; GP; General practitioner; Lung cancer; Lung cancer screening; Oncology; Primary care.

Figures

Fig. 1
Fig. 1
Positive predictive values (%) for lung cancer for individual risk markers, and for pairs of risk markers in combination (against a background risk of 0.18%). (1) The top row (bold) gives the PPV for an individual feature. The cells along the diagonal relate to the PPV when the same feature has been reported twice. Other cells show the PPV when a patient has two different features. (2) The top figure in each cell is the PPV. It has only been calculated when a minimum of ten cases had the feature or combination of features. The two other figures are the 95% CIs for the PPV. These have not been calculated when any cell in the 2 × 2 table was below 10. (3) The yellow shading is when the PPV is above 1%. The amber shading is when the PPV is above 2%. The red shading is for PPVs above 5.0%. Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer Nature. Ref. [54]

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210.
    1. Cancer registration statistics, England, 2016 Office for National Statistics 2018. . Accessed 17 Sept 2018.
    1. All data related to Deaths registered in England and Wales: 2017: Office for National Statistics. 2018. . Accessed 17 Sept 2018.
    1. Breast cancer survival statistics: Cancer Research UK. 2014. . Updated 27 Nov 2014, 29 Sept 2018.
    1. Prostate cancer survival statistics: Cancer Research UK. . Updated 9 Dec 2014. 29 Sept 2018.
    1. Bowel cancer survival statistics: Cancer Research UK. 2014. . Updated 1 Dec 2014, 29 Sept 2018.
    1. Lung cancer survival statistics: Cancer Research UK. . Accessed 16 May 2018.
    1. Fukuoka M, Wu Y-L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol. 2011;29(21):2866–2874. doi: 10.1200/JCO.2010.33.4235.
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi: 10.1016/S1470-2045(11)70393-X.
    1. Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi: 10.1056/NEJMoa1408440.
    1. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153–5159. doi: 10.1200/JCO.2010.30.0731.
    1. NCLA annual report 2017: Royal College of Physicians. 2018. . Accessed 17 Sept 2018.
    1. Hamilton W. Five misconceptions in cancer diagnosis. Br J Gen Pract. 2009;59(563):441–447. doi: 10.3399/bjgp09X420860.
    1. Demagny L, Holtedahl K, Bachimont J, Thorsen T, Letourmy A, Bungener M. General practitioners’ role in cancer care: a French-Norwegian study. BMC Res Notes. 2009;2(1):200. doi: 10.1186/1756-0500-2-200.
    1. Tørring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer. 2013;49(9):2187–2198. doi: 10.1016/j.ejca.2013.01.025.
    1. Ewing M, Naredi P, Nemes S, Zhang C, Månsson J. Increased consultation frequency in primary care, a risk marker for cancer: a case–control study. Scand J Prim Health Care. 2016;34(2):205–212. doi: 10.1080/02813432.2016.1183692.
    1. Iyen-Omofoman B, Tata LJ, Baldwin DR, Smith CJ, Hubbard RB. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax. 2013;68(5):451–459. doi: 10.1136/thoraxjnl-2012-202348.
    1. Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. Br J Gen Pract. 2018;68(666):e63–e72. doi: 10.3399/bjgp17X694169.
    1. Lyratzopoulos G, Abel GA, McPhail S, Neal RD, Rubin GP. Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer. 2013;108:686. doi: 10.1038/bjc.2013.1.
    1. McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112 (Suppl 1):S108–S115. doi: 10.1038/bjc.2015.49.
    1. National Cancer Intelligence Network. Routes to diagnosis. London: Public Health England. 2018. . Accessed 27 Oct 2018.
    1. Rose PW, Rubin G, Perera-Salazar R, et al. Explaining variation in cancer survival between 11 jurisdictions in the International Cancer Benchmarking Partnership: a primary care vignette survey. BMJ Open. 2015;5(5):e007212. 10.1136/bmjopen-2014-007212.
    1. Vedsted P, Olesen F. Are the serious problems in cancer survival partly rooted in gatekeeper principles? An ecologic study. Br J Gen Pract. 2011;61(589):e508–e512. doi: 10.3399/bjgp11X588484.
    1. Brown KF, Rumgay H, Dunlop C, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118(8):1130–1141. doi: 10.1038/s41416-018-0029-6.
    1. Villeneuve P, Mao Y. Lifetime probability of developing lung cancer. Can J Public Health. 1994;85(6):385–388.
    1. Lubin JH, Caporaso NE. Cigarette smoking and lung cancer: modeling total exposure and intensity. Cancer Epidemiol Biomark Prev. 2006;15(3):517–523. doi: 10.1158/1055-9965.EPI-05-0863.
    1. Doll R, Peto R, Boreham J, Sutherland I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br J Cancer. 2005;92:426. doi: 10.1038/sj.bjc.6602359.
    1. Peto J. That lung cancer incidence falls in ex-smokers: misconceptions 2. Br J Cancer. 2011;104(3):389. doi: 10.1038/sj.bjc.6606080.
    1. Pelosof L, Ahn C, Gao A, et al. Proportion of never-smoker non-small cell lung cancer patients at three diverse institutions. J Natl Cancer Inst. 2017;109(7):295. doi: 10.1093/jnci/djw295.
    1. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163(12):1475–1480. doi: 10.1001/archinte.163.12.1475.
    1. Skillrud DM, Offord KP, Miller R. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. Ann Intern Med. 1986;105(4):503–507. doi: 10.7326/0003-4819-105-4-503.
    1. Kiri VA, Soriano JB, Visick G, Fabbri LM. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2009;19:57. doi: 10.4104/pcrj.2009.00048.
    1. Young RP, Duan F, Chiles C, et al. Airflow limitation and histology shift in the National Lung Screening Trial. The NLST-ACRIN cohort substudy. Am J Respir Crit Care Med. 2015;192(9):1060–1067. doi: 10.1164/rccm.201505-0894OC.
    1. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):121–127. doi: 10.1016/j.lungcan.2015.08.017.
    1. McCormack V, Peto J, Byrnes G, Straif K, Boffetta P. Estimating the asbestos-related lung cancer burden from mesothelioma mortality. Br J Cancer. 2012;106:575. doi: 10.1038/bjc.2011.563.
    1. Brown T, Darnton A, Fortunato L, Rushton L. Occupational cancer in Britain. Br J Cancer. 2012;107:S56. doi: 10.1038/bjc.2012.119.
    1. Cancer Research UK. Lung cancer statistics. 2018. . Accessed 28 June 2018.
    1. Cancer Research UK. Tobacco statistics. 2014. . Accessed 6 Sept 2018.
    1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801. doi: 10.1016/S1470-2045(12)70211-5.
    1. Schwartz AG, Ruckdeschel JC. Familial lung cancer. Am J Respir Crit Care Med. 2006;173(1):16–22. doi: 10.1164/rccm.200502-235PP.
    1. Coté ML, Liu M, Bonassi S, et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48(13):1957–1968. doi: 10.1016/j.ejca.2012.01.038.
    1. Kamo K, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T. Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. Jpn J Clin Oncol. 2008;38(8):571–576. doi: 10.1093/jjco/hyn061.
    1. National Institute for Health and Care Excellence. NICE guideline [NG12]. Suspected cancer: recognition and referral 2015. . Updated July 2017, 13th Aug 2018.
    1. Hamilton W. Towards earlier diagnosis of cancer in primary care: a population-based case-control study of colorectal, lung and prostate cancer. MD thesis, Bristol. 2005.
    1. Shim J, Brindle L, Simon M, George S. A systematic review of symptomatic diagnosis of lung cancer. Fam Pract. 2014;31(2):137–148. doi: 10.1093/fampra/cmt076.
    1. Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059–1065. doi: 10.1136/thx.2005.045880.
    1. Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015;112:S6. doi: 10.1038/bjc.2015.30.
    1. National Cancer Intelligence Network. Routes to diagnosis 2016-2013 workbook. London: NCIN. 2015. . Accessed 14 Aug 2018.
    1. Beckett P, Tata LJ, Hubbard RB. Risk factors and survival outcome for non-elective referral in non-small cell lung cancer patients—analysis based on the National Lung Cancer Audit. Lung Cancer. 2014;83(3):396–400. doi: 10.1016/j.lungcan.2013.10.010.
    1. Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake MD. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br J Cancer. 2014;112:207. doi: 10.1038/bjc.2014.596.
    1. Kennedy MPT, Cheyne L, Darby M, et al. Lung cancer stage-shift following a symptom awareness campaign. Thorax. 2018;73(12):1128–1136. doi: 10.1136/thoraxjnl-2018-211842.
    1. Peake M. National cancer registration and analysis service. Be clear on cancer: regional and national lung cancer awareness campaigns 2011 to 2014. Final evaluation results—executive headlines. London: Public Health England. 2018. Available . Accessed 27 Nov 2018.
    1. Emery JD, Gray V, Walter FM, et al. The improving rural cancer outcomes trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia. Br J Cancer. 2017;117:1459. doi: 10.1038/bjc.2017.310.
    1. Hamilton W. The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients. Br J Cancer. 2009;101:S80. doi: 10.1038/sj.bjc.6605396.
    1. Hamilton W, Green T, Martins T, Elliott K, Rubin G, Macleod U. Evaluation of risk assessment tools for suspected cancer in general practice: a cohort study. Br J Gen Pract. 2013;63(606):e30–e36. doi: 10.3399/bjgp13X660751.
    1. Hippisley-Cox J, Coupland C. Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2011;61(592):e715–e723. doi: 10.3399/bjgp11X606627.
    1. Neal RD, Hamilton W, Rogers TK. Lung cancer. BMJ. 2014;349:g6560. doi: 10.1136/bmj.g6560.
    1. Hamilton W. Cancer diagnosis in primary care. Br J Gen Pract. 2010;60(571):121–128. doi: 10.3399/bjgp10X483175.
    1. Barraclough K. New NICE guidance on referral for cancer. BMJ. 2015;351:h3640. doi: 10.1136/bmj.h3640.
    1. Nicholson BD, Mant D, Bankhead C. Can safety-netting improve cancer detection in patients with vague symptoms? BMJ. 2016;355:i5515.
    1. Mitchell ED, Rubin G, Macleod U. Understanding diagnosis of lung cancer in primary care: qualitative synthesis of significant event audit reports. Br J Gen Pract. 2013;63(606):e37–e46. doi: 10.3399/bjgp13X660760.
    1. Jarvis S. Playing it safe-safety netting advice. 2016. . Updated 11 Mar 2016. 19 Sept 2018.
    1. Public Health England. Patient dose information: guidance. 2008. . Accessed 27 Nov 2018.
    1. Stapley S, Sharp D, Hamilton W. Negative chest X-rays in primary care patients with lung cancer. Br J Gen Pract. 2006;56(529):570–573.
    1. Fernandez V, Alonso JL, Munuera L, et al. Analysis of lung cancer cases diagnosed in an internal medicine department: from January 2001 to September 2006. An Sist Sanit Navar. 2007;30(3):353–362. doi: 10.4321/S1137-66272007000500004.
    1. Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56(532):863–868.
    1. Mitchell E, Macleod U, Rubin G. Report for the national awareness and early diagnosis initiative. Cancer in primary care. An analysis of significant event audits (SEA) for cancer diagnosis: 2008–2009. Department of Health National Cancer Action Team and North of England Cancer Network. 2009. . Accessed 27 Nov 2018.
    1. Athey VL, Suckling RJ, Tod AM, Walters SJ, Rogers TK. Early diagnosis of lung cancer: evaluation of a community-based social marketing intervention. Thorax. 2012;67(5):412–7.
    1. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):1–55. doi: 10.1136/thx.2009.121434.
    1. Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. 2011;171(13):1193–1198. doi: 10.1001/archinternmed.2011.155.
    1. National Lung Screening Trial Research Team Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–1991. doi: 10.1056/NEJMoa1209120.
    1. National Institute for Health and Care Excellence. NICE guideline [CG121]. Lung cancer: diagnosis and management. 2011. . Accessed 14 Aug 2018.
    1. Lung Clinical Expert Group. National optimal lung cancer pathway. 2017. . Accessed 27 Nov 2018.
    1. Healthcare resource statistics-technical resources and medical technology. Eurostat; 2017. . Accessed 14 Aug 2018.
    1. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277–2284. doi: 10.1056/NEJMra072149.
    1. Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the national lung screening trial. Am J Roentgenol. 2011;197(5):1165–1169. doi: 10.2214/AJR.11.6533.
    1. Millett D. Why GPs need better access to diagnostic cancer scans. GP. 2014. .
    1. Guldbrandt LM, Rasmussen RR, Ramussen F, Vedsted P. Implementing direct access to low-dose computed tomography in general practice-method, adaption and outcome. PLoS One. 2014;9(11):1–9. doi: 10.1371/journal.pone.0112162.
    1. Arooj P, Bredin E, Henry MT, et al. Bronchoscopy in the investigation of outpatients with hemoptysis at a lung cancer clinic. Respir Med. 2018;139:1–5. doi: 10.1016/j.rmed.2018.04.007.
    1. Kennedy MP, Arooj P, Henry MT. Bronchoscopy is not required in patients being investigated for hemoptysis at a rapid access cancer clinic with normal CT scan. Chest. 2018;154(2):465–466. doi: 10.1016/j.chest.2018.03.060.
    1. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality. The prostate, lung, colorectal, and ovarian (PLCO) randomized trial. J Am Med Assoc. 2011;306(17):1865–1873. doi: 10.1001/jama.2011.1591.
    1. National Lung Screening Trial Research Team. Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi: 10.1056/NEJMoa1102873.
    1. Moyer VA. On behalf of the USPSTF. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–338. doi: 10.7326/M13-2771.
    1. Pham D, Bhandari S, Oechsli M, Pinkston CM, Kloecker GH. Lung cancer screening rates: data from the lung cancer screening registry. J Clin Oncol. 2018;36(no. 15_suppl):6504.
    1. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278–1281. doi: 10.1001/jamaoncol.2016.6416.
    1. Baldwin DR, ten Haaf K, Rawlinson J, Callister MEJ. Low dose CT screening for lung cancer. BMJ. 2017;359:j5742.
    1. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–e766. doi: 10.1016/S1470-2045(17)30861-6.
    1. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54(2):177–184. doi: 10.1016/j.lungcan.2006.08.006.
    1. Rampinelli C, De Marco P, Origgi D, et al. Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ. 2017;356:j347. doi: 10.1136/bmj.j347.
    1. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–2429. doi: 10.1001/jama.2012.5521.
    1. Ruparel M, Quaife SL, Navani N, Wardle J, Janes SM, Baldwin DR. Pulmonary nodules and CT screening: the past, present and future. Thorax. 2016;71(4):367–375. doi: 10.1136/thoraxjnl-2015-208107.
    1. Bach PB. Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax. 2008;63(4):298–300. doi: 10.1136/thx.2007.082990.
    1. ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Commun Health. 2015;69(11):1035–1039. doi: 10.1136/jech-2014-204079.
    1. Heleno B, Siersma V, Brodersen J. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening: a secondary analysis of the Danish lung cancer screening trial. JAMA Intern Med. 2018;178(10):1420–1422. doi: 10.1001/jamainternmed.2018.3056.
    1. Brenner AT, Malo TL, Margolis M, et al. Evaluating shared decision making for lung cancer screening. JAMA Intern Med. 2018;178(10):1311–1316. doi: 10.1001/jamainternmed.2018.3054.
    1. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19(3):154–156. doi: 10.1258/jms.2012.012010.
    1. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2007;98:270. doi: 10.1038/sj.bjc.6604158.
    1. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–736. doi: 10.1056/NEJMoa1211776.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa